Ethyl eicosapentaenoic acid

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

Retrieved on: 
Friday, December 1, 2023
FDA, Health, General Health, Research, Pharmaceutical, Science, Diet, DSM-IV codes, EPA, NYSE, Business development, Organization, 1G, Constipation, Patient, Atrial fibrillation, Peripheral edema, Partnership, Eicosapentaenoic acid, Medication, Gout, Hypertriglyceridemia, Stride, Ethyl eicosapentaenoic acid

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.
  • The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023.
  • Icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl ester of eicosapentaenoic acid (EPA) that is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
  • “The launch of Icosapent ethyl is another essential medicine that we’ve added to our portfolio.”
    “We are thrilled to announce our partnership with Amneal Pharmaceuticals for Icosapent ethyl acid soft gelatin capsules.

Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research

Retrieved on: 
Wednesday, October 18, 2023
DHA, Salmon, Food, Pressure, Ethyl eicosapentaenoic acid, Professor, Intellectual property, Dietary supplement, EPA, Eicosapentaenoic acid, Rothamsted Research, Yield10 Bioscience, Rothamsted, Oil, Consistency, Sustainability, Aquaculture, Camelina

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”).

Key Points: 
  • WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”).
  • In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina sativa (“Camelina”).
  • As part of the collaboration agreement, Yield10 received an exclusive option to sign a global, exclusive license agreement for the technology.
  • The technology developed by Rothamsted enables the sustainable, plant-based production of omega-3 nutritional oils in Camelina.

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Retrieved on: 
Wednesday, July 26, 2023
Abstract, Risk, ESC Congress, MB, European Society of Cardiology, EST, Research, Biomarker, CH.B, MACE, Amarin, Professional corporation, IPE, Congress, EPA, Ethyl eicosapentaenoic acid, Patient, Eicosapentaenoic acid, ESC, SVP, MPH, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.
  • This new research includes, along with other topics, the review of the contribution of eicosapentaenoic acid (EPA) and other biomarkers to MACE reduction by icosapent ethyl (IPE).
  • Featured Amarin-supported abstracts to be presented at ESC Congress 2023 include:
    -Available: August 26 at 9:24 CET (3:24 a.m. EST) in Lisbon Room
    Session: What's new in lipid lowering?
  • CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin.

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Retrieved on: 
Friday, May 12, 2023
CT, Plaque, Myocardial infarction, Diabetes, MB, Macrophage, NIRF, Triglyceride, Cardiovascular disease, Radiology, CAD, CTA, Research, Loyola University, IVUS, CH.B, Atherosclerosis, Amarin, Professional corporation, European Heart Journal: Cardiovascular Imaging, Ethyl eicosapentaenoic acid, Animal, Computed tomography angiography, Patient, European Heart Journal, Molecular imaging, American Heart, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Key Points: 
  • EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
  • VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
  • “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
  • We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."

Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders

Retrieved on: 
Friday, February 17, 2023
Finance, Health, Professional Services, Pharmaceutical, Cardiology, MAKE, Sarissa, Patient, Sale, BUT, Sequah Medicine Company, Amarin Corporation, NOT, Wall Street, Mass meeting, Professional corporation, Annual general meeting, Glenview Capital Management, Internet service provider, Auction, Ethyl eicosapentaenoic acid, Amarin

Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below:
    Amarin shareholders face an important decision at our upcoming shareholder meeting.
  • The value of Vascepa, however, continues to be wasted by the company due to its mismanagement and poor capital allocation decisions.
  • Visit our website at www.freeamarin.com for helpful information about Sarissa and the need for change at Amarin.
  • The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023.

Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders

Retrieved on: 
Wednesday, February 1, 2023
Finance, Health, Professional Services, Pharmaceutical, Cardiology, Sarissa, Kareem, Patient, Sale, Letter, Sequah Medicine Company, Optimism, Interview, DEADLINE, Wall Street, BLUE, ONE, Mass meeting, Professional corporation, Internet, INTERNET, Annual general meeting, Glenview Capital Management, Management, Internet service provider, Bank, Cryptocurrency, Holding company, Audit, Security (finance), Auction, Ethyl eicosapentaenoic acid, Amarin

Sarissa Capital Management LP (“Sarissa”) today issued the following letter to fellow shareholders of Amarin Corporation plc (NASDAQ: AMRN):

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued the following letter to fellow shareholders of Amarin Corporation plc (NASDAQ: AMRN):
    Amarin shareholders face an important decision at our upcoming shareholder meeting.
  • Sarissa is one of the largest shareholders at Amarin because we, like you, believe in Vascepa and its potential.
  • Most importantly, our candidates will work collaboratively with the company to ensure that Amarin is run for the benefit of shareholders.
  • VOTE THE BLUE CARD “FOR” THE ELECTION OF THE SARISSA NOMINEES AND “FOR” THE REMOVAL OF CHAIRMAN PER WOLD-OLSEN BEFORE THE DEADLINE TO VOTE – 10:00 A.M. NEW YORK TIME ON FEBRUARY 22, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN

Retrieved on: 
Wednesday, May 18, 2022
News, NASDAQ, LLP, Pomerantz, GLOBE, COVID-19, Professional corporation, Company, Amarin Corporation, Pharmaceutical industry, Ethyl eicosapentaenoic acid

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN).

Key Points: 
  • NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN).
  • The investigation concerns whether Amarin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On May 4, 2022, pre-market, Amarin issued a press release reporting its financial results for the first quarter of 2022 and providing business updates.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

National Advertising Division Finds Innovix Pharma Qualified Claims Supported; Recommends Certain OmegaVia Performance Claims be Discontinued

Retrieved on: 
Tuesday, April 26, 2022
EPA, DHA, Advertising, HUGE, Science, TG, NAD, Ethyl eicosapentaenoic acid, Dietary supplement, Diet, Privacy, Triglyceride, CARU, Depression, Better Business Bureau, Association of National Advertisers, Safety, Blood pressure, Multimedia, FDA, Exercise, Council, Disclosure

However, NAD recommended that the advertiser discontinue the challenged product performance claims and testimonials relating to heart health and triglyceride management.

Key Points: 
  • However, NAD recommended that the advertiser discontinue the challenged product performance claims and testimonials relating to heart health and triglyceride management.
  • The claims at issue were challenged by Amarin Pharma, Inc., the manufacturer of the FDA-approved cardiovascular drug Vascepa.
  • The challenger took issue with Innovix's heart health claims and testimonials, including those related to triglyceride and blood pressure management.
  • NAD's jurisdiction extends only to assessing the truthfulness and accuracy of advertising claims made in national advertising.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation plc – AMRN

Retrieved on: 
Monday, November 1, 2021
LLP, Ethyl eicosapentaenoic acid, Retirement, Pomerantz, United States Court of Appeals for the Federal Circuit, NASDAQ, Anders (singer), District, Patent, Supreme, Company, Supreme court, District court, Amarin Corporation, News, Professional corporation, GLOBE, List, Online gambling, Private investigator

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ:AMRN).

Key Points: 
  • NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc (Amarin or the Company) (NASDAQ:AMRN).
  • The investigation concerns whether Amarin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On this news, Amarins stock price fell over 70.5% to close at $4.00 per share on March 31, 2020.
  • On April 12, 2021, Amarin announced the retirement of John F. Thero as the Companys President and Chief Executive Officer.

The Law Offices of Frank R. Cruz Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

Retrieved on: 
Thursday, October 28, 2021
Legal, Professional Services, Law of the United Kingdom, Ethyl eicosapentaenoic acid, Nevada, Twitter, NASDAQ, Suite, Anders (singer), District, Patent, Supreme court, District court, Amarin Corporation, News, Professional corporation, Law, Private investigator

The Law Offices of Frank R. Cruz announces an investigation of Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On this news, Amarins share price fell $9.58, or approximately 70.5%, to close at $4.00 per share on March 31, 2020, thereby injuring investors.
  • On June 21, 2021, investors learned that the Supreme Court rejected the Companys bid to revive its Vascepa patents.
  • On this news, Amarins share price fell 5.2%, to close at $4.70 per share on June 21, 2021, further injuring investors.